ProCE Banner Activity

Monoclonal Antibodies for Outpatient Treatment of COVID-19: The Last Stand

Clinical Thought
Monoclonal antibodies were previously a cornerstone of therapy for early COVID-19, but emerging omicron subvariants have compromised their in vitro activity. What does this mean for our COVID-19 treatment paradigm?

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.

Share

Faculty

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD: advisor: Kintor and research: NIH-funded site investigator for casirivimab/imdevimab prevention trial.